NEW YORK, July 21 /PRNewswire-Asia-FirstCall/ -- American Oriental Bioengineering, Inc. (NYSE: AOB), ("the Company" or "AOBO"), a pharmaceutical company dedicated to improving health through the development, manufacture and commercialization of a broad range of prescription and over the counter ("OTC") products in China, today announced that AOBO was honorably elected as one of the "Top 20 Most Competitive Public Pharmaceutical Companies in China." This event was jointly organized by China's leading healthcare industry associations, including the Chinese Pharmaceutical Enterprise Association and its publication, Healthcare Executive Magazine, and China's Center for Pharmaco-economics and Outcomes Research (CCPOR) at Beijing University, where an awards ceremony was held today.
The 20 listed companies were selected from 132 Chinese pharmaceutical companies listed in Shanghai, Shenzhen, Hong Kong, Singapore, New York or on NASDAQ, as of February of this year. The selection criteria were based on the companies' management capabilities, brand recognition, financial strength, resource accessibility and quality of key team members.
Mr. Tony Liu, Chairman and Chief Executive Officer of American Oriental Bioengineering, commented, "We are very honored to receive this recognition by the industry. This award speaks to the strength of our brand value and competitiveness in the changing environment. We will continue to focus on creating greater value for investors."
About American Oriental Bioengineering, Inc.
American Oriental Bioengineering, Inc. is a China-based pharmaceutical company dedicated to improving health through the development, manufacture and commercialization of a broad range of prescription and over the counter products.
Statements made in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties that may cause actual results to differ materially from those set forth in these statements. The economic, competitive, governmental, technological and other factors identified in the Company's filings with the Securities and Exchange Commission, including the Form 10-K for the year ended December 31, 2008, may cause actual results or events to differ materially from those described in the forward looking statements in this press release. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise.
|SOURCE American Oriental Bioengineering, Inc.|
Copyright©2009 PR Newswire.
All rights reserved